Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: Results of a prospective, double-blind, randomized trial

T. Walsh, A. K. Morris, L. M. Holle, N. Callander, P. Bradshaw, A. W. Valley, G. Clark, C. O. Freytes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The serotonin type-3 (5-HT3) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in efficacy or adverse effects exist between two such agents, ondansetron and granisetron, during conditioning therapy for hematopoietic stem cell transplantation (HSCT). Patients were randomized to receive either ondansetron 0.15 mg/kg intravenously every 8h or granisetron 10 μg/kg intravenously daily. Additionally, all patients received scheduled dexamethasone and lorazepam. Prophylaxis was continued until 24 h after completion of chemotherapy. Nausea and distress were measured subjectively with visual analog scales and emetic episodes were quantified. Of the 110 randomized patients, 96 were evaluable for efficacy and safety. No significant differences in efficacy were observed between the ondansetron- and granisetron-treated patients, evaluated by comparing the degree of nausea and distress, number of emetic episodes and overall control of emesis. The adverse effects were also comparable and no patients were removed from study because of severe toxicities. This trial demonstrates that ondansetron and granisetron are equally effective at preventing acute N/V associated with conditioning therapy frequently used for HSCT. The agent of choice should be based on drug acquisition cost or preference.

Original languageEnglish (US)
Pages (from-to)963-968
Number of pages6
JournalBone Marrow Transplantation
Volume34
Issue number11
DOIs
StatePublished - Dec 2004

Fingerprint

Granisetron
Ondansetron
Hematopoietic Stem Cells
Nausea
Vomiting
Transplants
Emetics
Behavior Therapy
Hematopoietic Stem Cell Transplantation
Serotonin 5-HT3 Receptor Antagonists
Lorazepam
Drug Therapy
Drug Costs
Visual Analog Scale
Dexamethasone
Serotonin
Safety

Keywords

  • Granisetron
  • Hematopoietic stem cell transplantation
  • Nausea
  • Ondansetron
  • Vomiting

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients : Results of a prospective, double-blind, randomized trial. / Walsh, T.; Morris, A. K.; Holle, L. M.; Callander, N.; Bradshaw, P.; Valley, A. W.; Clark, G.; Freytes, C. O.

In: Bone Marrow Transplantation, Vol. 34, No. 11, 12.2004, p. 963-968.

Research output: Contribution to journalArticle

Walsh, T. ; Morris, A. K. ; Holle, L. M. ; Callander, N. ; Bradshaw, P. ; Valley, A. W. ; Clark, G. ; Freytes, C. O. / Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients : Results of a prospective, double-blind, randomized trial. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 11. pp. 963-968.
@article{a3660c5878e34a7aad7a2319e7885e4b,
title = "Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: Results of a prospective, double-blind, randomized trial",
abstract = "The serotonin type-3 (5-HT3) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in efficacy or adverse effects exist between two such agents, ondansetron and granisetron, during conditioning therapy for hematopoietic stem cell transplantation (HSCT). Patients were randomized to receive either ondansetron 0.15 mg/kg intravenously every 8h or granisetron 10 μg/kg intravenously daily. Additionally, all patients received scheduled dexamethasone and lorazepam. Prophylaxis was continued until 24 h after completion of chemotherapy. Nausea and distress were measured subjectively with visual analog scales and emetic episodes were quantified. Of the 110 randomized patients, 96 were evaluable for efficacy and safety. No significant differences in efficacy were observed between the ondansetron- and granisetron-treated patients, evaluated by comparing the degree of nausea and distress, number of emetic episodes and overall control of emesis. The adverse effects were also comparable and no patients were removed from study because of severe toxicities. This trial demonstrates that ondansetron and granisetron are equally effective at preventing acute N/V associated with conditioning therapy frequently used for HSCT. The agent of choice should be based on drug acquisition cost or preference.",
keywords = "Granisetron, Hematopoietic stem cell transplantation, Nausea, Ondansetron, Vomiting",
author = "T. Walsh and Morris, {A. K.} and Holle, {L. M.} and N. Callander and P. Bradshaw and Valley, {A. W.} and G. Clark and Freytes, {C. O.}",
year = "2004",
month = "12",
doi = "10.1038/sj.bmt.1704714",
language = "English (US)",
volume = "34",
pages = "963--968",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients

T2 - Results of a prospective, double-blind, randomized trial

AU - Walsh, T.

AU - Morris, A. K.

AU - Holle, L. M.

AU - Callander, N.

AU - Bradshaw, P.

AU - Valley, A. W.

AU - Clark, G.

AU - Freytes, C. O.

PY - 2004/12

Y1 - 2004/12

N2 - The serotonin type-3 (5-HT3) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in efficacy or adverse effects exist between two such agents, ondansetron and granisetron, during conditioning therapy for hematopoietic stem cell transplantation (HSCT). Patients were randomized to receive either ondansetron 0.15 mg/kg intravenously every 8h or granisetron 10 μg/kg intravenously daily. Additionally, all patients received scheduled dexamethasone and lorazepam. Prophylaxis was continued until 24 h after completion of chemotherapy. Nausea and distress were measured subjectively with visual analog scales and emetic episodes were quantified. Of the 110 randomized patients, 96 were evaluable for efficacy and safety. No significant differences in efficacy were observed between the ondansetron- and granisetron-treated patients, evaluated by comparing the degree of nausea and distress, number of emetic episodes and overall control of emesis. The adverse effects were also comparable and no patients were removed from study because of severe toxicities. This trial demonstrates that ondansetron and granisetron are equally effective at preventing acute N/V associated with conditioning therapy frequently used for HSCT. The agent of choice should be based on drug acquisition cost or preference.

AB - The serotonin type-3 (5-HT3) antagonists represent a significant advance in the prevention of acute nausea and vomiting (N/V) from highly emetogenic chemotherapy. We sought to determine if any differences in efficacy or adverse effects exist between two such agents, ondansetron and granisetron, during conditioning therapy for hematopoietic stem cell transplantation (HSCT). Patients were randomized to receive either ondansetron 0.15 mg/kg intravenously every 8h or granisetron 10 μg/kg intravenously daily. Additionally, all patients received scheduled dexamethasone and lorazepam. Prophylaxis was continued until 24 h after completion of chemotherapy. Nausea and distress were measured subjectively with visual analog scales and emetic episodes were quantified. Of the 110 randomized patients, 96 were evaluable for efficacy and safety. No significant differences in efficacy were observed between the ondansetron- and granisetron-treated patients, evaluated by comparing the degree of nausea and distress, number of emetic episodes and overall control of emesis. The adverse effects were also comparable and no patients were removed from study because of severe toxicities. This trial demonstrates that ondansetron and granisetron are equally effective at preventing acute N/V associated with conditioning therapy frequently used for HSCT. The agent of choice should be based on drug acquisition cost or preference.

KW - Granisetron

KW - Hematopoietic stem cell transplantation

KW - Nausea

KW - Ondansetron

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=10044298251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10044298251&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704714

DO - 10.1038/sj.bmt.1704714

M3 - Article

C2 - 15489869

AN - SCOPUS:10044298251

VL - 34

SP - 963

EP - 968

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -